Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Turk Patoloji Derg ; 36(2): 164-168, 2020.
Article in English | MEDLINE | ID: mdl-30632122

ABSTRACT

Primary thyroid lymphomas are pretty uncommon, and constitute about 5% of the neoplasms of this organ. Spontaneous tumor regression is defined as the total or partial disappearance of a tumor as proven by microscope without treatment or under inadequate treatment. It is estimated to happen in one out of 60,000-100,000 cases. We present a case of primary thyroid lymphoma with spontaneous regression after diagnostic puncture and corroborated with hemithyroidectomy at four months. The patient died after twenty-six months of follow-up because of endocarditis and there was no relapse at any time.


Subject(s)
Lymphoma, Large B-Cell, Diffuse/pathology , Neoplasm Regression, Spontaneous/pathology , Thyroid Neoplasms/pathology , Female , Humans , Middle Aged
2.
J Clin Apher ; 34(4): 461-467, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30817045

ABSTRACT

INTRODUCTION: Autologous bone marrow transplantation is a component of the malignant hemopathy therapy. The preferred mobilization and collection method is apheresis. The aim of this study is to compare three protocols analyzing the effect of plerixafor, higher dose of G-CSF and large volume leukapheresis (LVL). MATERIALS AND METHODS: A retrospective cohort study including 119 patients referred for mobilization. Three protocols were compared: (a) G-CSF 10 µg/kg/day subcutaneous (sc) × 4 days mobilizing 1 to 1.5 blood volumes. (b) G-CSF 10 µg/kg/day sc × 4 days + plerixafor 0.24 mg/kg/day sc preventively or as a rescue agent mobilizing 1 to 1.5 blood volumes. (c) G-CSF 20 µg/kg/day sc × 4 days ± plerixafor 0.24 mg/kg/day sc preventively or as a rescue agent mobilizing 3 to 4 blood volumes. RESULTS: The average number of days of apheresis was reduced to 1.37 with protocol 3. The average cost per patient was reduced by 67% compared with protocol 2 and increased by only 5% compared with protocol 1, reducing the failure rate to 0%. CONCLUSION: Adding preemptive or rescue plerixafor (protocol 2) to G-CSF 10 µg/kg/day alone (protocol 1) did not improve the days of apheresis nor the number of CD34+ cells collected but had higher cost and failure rate. Using LVL, plerixafor and G-CSF 20 µg/kg/day (protocol 3) decreased the number of sessions to 1.37, reduced the failure rate to 0% and led to a significant increase in the number of CD34+ cells collected without toxicity and with a similar cost to protocol 1.


Subject(s)
Blood Component Removal/economics , Clinical Protocols/standards , Costs and Cost Analysis , Hematopoietic Stem Cell Mobilization/economics , Adult , Aged , Antigens, CD34/analysis , Benzylamines , Blood Component Removal/methods , Blood Volume , Cohort Studies , Cyclams , Drug Administration Schedule , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Hematopoietic Stem Cell Mobilization/methods , Heterocyclic Compounds/administration & dosage , Humans , Male , Middle Aged , Retrospective Studies , Time Factors
5.
Acta Haematol ; 141(1): 1-6, 2019.
Article in English | MEDLINE | ID: mdl-30428459

ABSTRACT

Multiparameter flow cytometry (MFC)-based clonality assessment is a powerful method of diagnosis and follow-up in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). However, the relevance of intraclonal heterogeneity in immunophenotypic studies remains poorly understood. The main objective of this work was to characterize the different immunophenotypic subclones in MGUS and MM patients and to investigate their correlation with disease stages. An 8-color MFC protocol with 17 markers was used to identify the subclones within the neoplastic compartment of 56 MGUS subjects, 151 newly diagnosed MM patients, 30 MM subjects in complete remission with detectable minimal residual disease, and 36 relapsed/refractory MM patients. Two or more clusters were observed in > 85% of MGUS subjects, 75% of stage I MM patients, and < 15% in stage III. Likewise, a significant correlation between the dominant subclone size, secondary cytogenetic features, and changes in the expression of CD27, CD44, and CD81 was detected. The loss of intraclonal equilibrium may be an important factor related with kinetics and risk of progression not well considered to date in MFC studies. The MFC strategy used in this work can provide useful biomarkers in MGUS and MM.


Subject(s)
Biomarkers/metabolism , Flow Cytometry/methods , Multiple Myeloma/diagnosis , Paraproteinemias/diagnosis , Chromosome Aberrations , Humans , Hyaluronan Receptors/metabolism , Immunophenotyping , Multiple Myeloma/metabolism , Multiple Myeloma/pathology , Neoplasm Staging , Paraproteinemias/metabolism , Paraproteinemias/pathology , Tetraspanin 28/metabolism , Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism
7.
Children (Basel) ; 4(12)2017 Dec 20.
Article in English | MEDLINE | ID: mdl-29261159

ABSTRACT

We describe an exceptional case of erythroid sarcoma in a pediatric patient as a growing orbital mass with no evidence of morphologic bone marrow involvement, who was finally diagnosed of pure erythroid sarcoma based on histopathology and flow cytometry criteria. We discuss the contribution of standardized eight-color flow cytometry as a rapid and reliable diagnostic method. The use of normal bone marrow databases allowed us to identify small aberrant populations in bone marrow and later confirm the diagnosis in the neoplastic tissue.

SELECTION OF CITATIONS
SEARCH DETAIL
...